Diabetes Core Update cover image

Diabetes Core Update – February 2023

Diabetes Core Update

00:00

Glucagon Increases Energy Expenditure

Terzepitide, a combination dual receptor agonist GLP one GIP and low and behold in the surmount trial last year, June in people with obesity and without diabetes 22% weight loss. glucagon for years has been like that medical student that you know has a lot of potential, but it just he hasn't matured yet. And we'll see how this combination peptide does long term through many other phases,. But it's very exciting we might have an even more powerful triple receptor agonist in the future.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app